|
Q2 FY2026
As of Nov 30, 2025
|
Q1 FY2026
As of Aug 31, 2025
|
Q4 FY2025
As of May 31, 2025
|
Q3 FY2025
As of Feb 28, 2025
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q3 FY2022
As of Feb 28, 2022
|
Q1 FY2022
As of Aug 31, 2021
|
Q4 FY2022
As of May 31, 2022
|
Q1 FY2021
As of Aug 31, 2020
|
Q3 FY2020
As of Feb 29, 2020
|
Q4 FY2020
As of May 31, 2020
|
Q1 FY2020
As of Aug 31, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | |||||||||||||
| Total current assets | |||||||||||||
| Total assets | |||||||||||||
| Accounts payable and accrued liabilities | |||||||||||||
| Due to related party | |||||||||||||
| Notes payable | |||||||||||||
| Total current liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Common stock, $0.00001 par value, 500,000,000 shares authorized, 37,997,373 and 37,997,373 shares issued and outstanding as of November 30, 2025 and May 31, 2025 , respectively | |||||||||||||
| Additional paid in capital | |||||||||||||
| Stock payable | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders' deficit | |||||||||||||
| Total liabilities and stockholders' deficit | |||||||||||||
| Series A Preferred stock, $0.00001 par value, 100,000,000 shares authorized, 5,850,000 and 5,850,000 shares issued and outstanding as of November 30, 2025 and May 31, 2025 , respectively | |||||||||||||
| Series A Preferred Stock | |||||||||||||
Loading...